AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Other Events
Item8.01. Other Events.
On June23, 2017, AVEO Pharmaceuticals, Inc. (the Company) issued
a press release announcing that the Committee for Medicinal
Products for Human Use of the European Medicines Agency made a
decision with respect to the marketing authorization application
for tivozanib in the treatment of renal cell carcinoma. The full
text of the press release issued in connection with the
announcement is filed as Exhibit99.1 to this Current Report on
Form 8-K. The information contained therein is incorporated
herein by reference.
Item9.01. Financial Statements and Exhibits.
(d) |
Exhibits |
| 99.1 | Press release issued by the Company on June23, 2017 |
AVEO PHARMACEUTICALS INC ExhibitEX-99.1 2 d410992dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 AVEO Oncology Announces Positive CHMP Opinion for Tivozanib as a Treatment of Advanced Renal Cell Carcinoma CAMBRIDGE,…To view the full exhibit click here About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
